SCHEMBL4494191

SCHEMBL4494191

COc1ccc(CNCCNC(=O)c2cccc(C(=O)N(C)CCN3CCC(OC(=O)N(c4ccccc4-c4ccccc4)N(C(=O)O)c4ccccc4-c4ccccc4)CC3)c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.43
CHRM3 P20309 3/20 0.42
ADRB2 P07550 2/20 0.42
CCR3 P51677 2/20 0.40
DRD2 P14416 1/20 0.39
SLC5A7 Q9GZV3 1/20 0.39
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
PTGIR P43119 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
DRD4 P21917 3/20 0.37
SMYD2 Q9NRG4 1/20 0.36
HTR1A P08908 1/20 0.36
CHRM5 P08912 1/20 0.36
CHRM1 P11229 1/20 0.36
ITK Q08881 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4483079 0.94 CHRM3 (0.44) CHRM2CHRM3ADRB2DRD2SLC5A7
SCHEMBL4471205 0.93 CCR3 (0.46) CHRM3ADRB2CCR3DRD2SLC5A7
SCHEMBL4484438 0.91 CHRM3 (0.43) CHRM2CHRM3ADRB2DRD2
SCHEMBL4494455 0.91 CHRM2 (0.43) CHRM2CHRM3ADRB2DRD2
SCHEMBL4493963 0.91 CHRM3 (0.45) CHRM2CHRM3ADRB2SLC5A7
SCHEMBL4493960 0.90 CHRM2 (0.42) CHRM2CHRM3ADRB2CCR3SLC5A7
SCHEMBL4490830 0.89 CHRM2 (0.44) CHRM2CHRM3ADRB2CCR3DRD2
SCHEMBL4475841 0.89 CHRM2 (0.43) CHRM2CHRM3ADRB2CCR3DRD2
SCHEMBL4491995 0.88 CHRM2 (0.41) CHRM2CHRM3ADRB2DRD2SLC5A7
SCHEMBL4479676 0.88 CARM1 (0.45) CHRM2CHRM3ADRB2DRD2SLC5A7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7632847-B2 Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-(3-[3-(4-hydroxybenzylamino)propionylamino]benzoylamino)ethyl)piperidin-4-yl ester THERAVANCE, INC. (US) 2009-12-15 US disclosed